Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis

The results indicate that auranofin is safe, superior to placebo and has steroid-sparing capacity in the treatment of elderly-onset rheumatoid arthritis

A. Glennas; T. K. Kvien; O. Andrup; O. Clarke-Jenssen; B. Karstensen; U. Brodin


Scholarcy highlights

  • We investigated whether auranofin was better than placebo, judged by clinical and radiographic outcome measures, and whether auranofin was safe and had steroid-sparing properties
  • Patients were considered eligible for the study if they had active disease defined as more than three swollen joints and elevated acute-phase reactants
  • Patients with temporal arteritis or polymyalgia rheumatica without arthritis were excluded, as were patients with major arthropathies other than elderly-onset rheumatoid arthritis, patients previously treated with gold-containing drugs, patients on oral prednisolone for other reasons than EORA or in doses exceeding 20 mg daily within the 4 preceding weeks, patients with chronic inflammatory bowel disease, liver or kidney disease, or other diseases which contraindicated the use of the study drug, prednisolone or non-steroidal anti-inflammatory drugs
  • The main result of the study is that the patients on auranofin adhered to therapy for a longer period of time than those on placebo, and managed well on a lower dose of prednisolone
  • The post hoc analysis by Dahl et al, stratifying patients by age Q 65 and e65 yr, examined a clinical trial on a mixed younger-onset rheumatoid arthritis and EORA population treated with either auranofin or parenteral gold
  • Compared to results obtained in other studies on younger-onset RA and younger patient populations, auranofin is not considered to be less effective or more toxic in elderly-onset rheumatoid arthritis

Need more features? Save interactive summary cards to your Scholarcy Library.